Evidence map›Paper›PMID 36680083›Full record

ArticleViruses2022

Inactivation of Ebola Virus and SARS-CoV-2 in Cell Culture Supernatants and Cell Pellets by Gamma Irradiation.

RuthMabel Boytz, Scott Seitz, Emily Gaudiano, J J Patten, Patrick T Keiser, John H Connor, Arlene H Sharpe, Robert A Davey

Abstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

RuthMabel BoytzDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0002-8524-8376
Scott SeitzDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0002-1254-2478
Emily GaudianoDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA.
J J PattenDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0002-9770-7525
Patrick T KeiserDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0002-3915-3659
John H ConnorDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0002-8867-7256
Arlene H SharpeDepartment of Immunology, Harvard Medical School, Boston, MA 02115, USA.
Robert A DaveyDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 02115, USA.ORCID 0000-0001-9168-2892

Funding

Regulatory Compliance CoreUC7AI095321 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kevin Michael Tuohey · 2014 to 2026
$159.3M
Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
Antiviral Lead Identification to Treat Filovirus InfectionsR01AI128364 · NIAID · PURDUE UNIVERSITY · PI DAVEY, ROBERT A, DAVISSON, VINCENT JO · 2019 to 2022
$2.6M
NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI128364NIAID NIH HHS UC7 AI095321
6 · The paper itself

Abstract

Viral pathogens with the potential to cause widespread disruption to human health and society continue to emerge or re-emerge around the world. Research on such viruses often involves high biocontainment laboratories (BSL3 or BSL4), but the development of diagnostics, vaccines and therapeutics often uses assays that are best performed at lower biocontainment. Reliable inactivation is necessary to allow removal of materials to these spaces and to ensure personnel safety. Here, we validate the use of gamma irradiation to inactivate culture supernatants and pellets of cells infected with a representative member of the Filovirus and Coronavirus families. We show that supernatants and cell pellets containing SARS-CoV-2 are readily inactivated with 1.9 MRad, while Ebola virus requires higher doses of 2.6 MRad for supernatants and 3.8 MRad for pellets. While these doses of radiation inactivate viruses, proinflammatory cytokines that are common markers of virus infection are still detected with low losses. The doses required for virus inactivation of supernatants are in line with previously reported values, but the inactivation of cell pellets has not been previously reported and enables new approaches for analysis of protein-based host responses to infection.

Indexed as

COVID-19EbolavirusHemorrhagic Fever, EbolaVirusesCell Culture TechniquesHumansSARS-CoV-2Virus InactivationcoronavirusEbola virusfilovirusinactivationradiation treatmentSARS-CoV-2sterilization

Identifiers

PMID36680083
PMCPMC9866162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.